ArticleFrontiers in immunology2025
Unveiling novel therapeutic mechanisms of Xinfeng capsule: modulating the ALKBH5-m6A-LINC00968 axis to alleviate oxidative stress-driven NETosis in rheumatoid arthritis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Rewiring immunity in rheumatoid arthritis: metabolic and epigenetic therapeutic strategies.Frontiers in pharmacology · 2026Review
- mFrontiers in immunology · 2026Review
- Epitranscriptomic regulation by m6A in immunity and autoimmune disorders: emerging mechanisms and clinical perspectives.Frontiers in immunology · 2026Review
- Study on the pro-inflammatory injury of neutrophil extracellular traps in gouty nephropathy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatoid arthritis (RA) is an autoimmune disease characterized by neutrophil infiltration and synovial hyperplasia. Neutrophil extracellular trap (NET) formation and subsequent oxidative stress-inflammation responses play a critical role in RA pathogenesis. Although m6A RNA methylation and the long non-coding RNA LINC00968 are known regulators in RA, their functions in neutrophils and the mechanisms underlying the therapeutic effect of the traditional Chinese medicine formula Xinfeng Capsule (XFC) remain unclear. Methods: A retrospective clinical study was first conducted involving 2,367 RA patients. Following propensity score matching, the effects of XFC on immune inflammatory markers and liver/kidney safety were evaluated. Subsequently, Results: Clinical results demonstrated that XFC significantly improved multiple immunoinflammatory markers in RA patients, including ESR, Hs-CRP, RF, CCP, NLR, and SII, without hepatorenal toxicity. Mechanistically, ALKBH5 was upregulated in the RA microenvironment, leading to reduced m6A methylation and enhanced expression of LINC00968. This axis promoted neutrophil hyperactivation, G1-phase arrest, and NETosis, accompanied by aggravated oxidative stress via the NADP+/NADPH pathway and elevated pro-inflammatory cytokine release (TNF-α, IL-6, and IL-17A). XFC treatment inhibited ALKBH5 activity, increased m6A methylation of LINC00968, and subsequently suppressed neutrophil dysregulation, NET formation, and oxidative stress-inflammation responses. These effects were consistently validated in rescue experiments involving ALKBH5 knockdown and LINC00968 overexpression. Conclusion: This study unveils a novel ALKBH5-m6A-LINC00968 signaling axis that critically regulates neutrophil hyperactivation and NETosis in RA. XFC attenuates the neutrophil-NET-synovial cell inflammatory cascade by targeting ALKBH5 and promoting m6A methylation of LINC00968, providing an epigenetically regulated therapeutic strategy for RA treatment within a traditional medicine framework.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.